Cabaletta Bio Stock News

In last trading session, Cabaletta Bio Inc. (NASDAQ:CABA) saw 0.31 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $4.24 trading at $0.13 or 3.16% at ring of the bell on the day assigns it a market valuation of $128.30M. That closing price of CABAs stock is Cabaletta Bio Inc. (NASDAQ:CABA) At $4.24: What To Do? Read More »

Cabaletta Bio Inc''s (NASDAQ: CABA ) DSG3-CAART fails to show biologic activity to date in the two lowest cell dose cohorts of Phase 1 trial mucosal Pemphigus Vulgaris (mPV). In cohort A1 (20 million DSG3-CAART cells), two of three participants had DSG3 autoantibody levels that rose over 20%, along with disease activity scores that worsened within six months after DSG3-CAART infusion. In cohort A2 Full story available on Benzinga.com

Cabaletta Bio Inc's (NASDAQ: CABA) DSG3-CAART fails to show biologic activity to date in the two lowest cell dose cohorts of Phase 1 trial mucosal Pemphigus Vulgaris (mPV). In cohort A1 (20 million

PHILADELPHIA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ: CABA ), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported top-line data on biologic activity from the two lowest dose cohorts in the DesCAARTes Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal Pemphigus Vulgaris (mPV). As of December 12, 2021, six patients, comprising the two lowest dose cohorts (20 million and 100 million DSG3-CAART cells administered without lymphodepletion) had completed three to six months of follow-up for evaluation of DSG3-CAART biologic activity. Patients enrolled had persistent mild to moderate disease severity prior to infusion despite receiving or having received systemic medication for treatment of their mPV symptoms prior to enrollment. Parameters being used in the trial to evaluate potential biologic activity include persistence of DSG3-CAART, change in level of DSG3 autoantibodies, change in mPV therapy or need for new systemic rescue therapy, and change in disease activity (e.g., as assessed by Pemphigus Disease Area Index (PDAI) and Oral Disease Severity Score (ODSS)).

State Street Corp lessened its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) by 88.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 22,807 shares of the companys stock after selling 181,509 shares during the period. State Street Corp owned 0.09% of Cabaletta Bio worth []

Northern Trust Corp trimmed its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) by 80.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 25,521 shares of the companys stock after selling 104,647 shares during the quarter. Northern Trust Corps holdings in Cabaletta Bio were worth $219,000 at the end of the most recent quarter. []

Cabaletta Bio, Inc. (NASDAQ:CABA) was the target of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 1,650,000 shares, a growth of 22.2% from the October 31st total of 1,350,000 shares. Based on an average daily trading volume, of 203,000 shares, the short-interest ratio []

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for p

The mean of analysts' price targets for Cabaletta Bio, Inc. (CABA) points to a 51.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am

– Chimeric AutoAntibody Receptor (CAAR) T cells specifically recognized and eliminated anti-PLA2R antibody-expressing B cells in vitro –

PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for

Cabaletta Bio Inc (NASDAQ: CABA) has announced 28-day data from the second dose cohort from the DesCAARTes Phase 1 trial of DSG3-CAART for mucosal-dominant pemphigus vulgaris (mPV). Related:   Cab

– No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of August 17 using 100 million cells in the second dose cohort   –

– Company continues to make progress on the DesCAARTes™ trial for DSG3-CAART; expects to report second and third cohort safety data in 3Q21 and 4Q21, respectively, and data on target engagement 3